Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Debiopharm Group

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 21
Average round size
info
The average size of a deal this fund participated in
$16M
Portfolio companies 14
Rounds per year 0.49
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 4
Key employees 2

Areas of investment

  • Biotechnology
  • Health Diagnostics
  • Genetics
  • Diagnostic Equipment
  • Medical Device
Summary

The company was established in Europe in Switzerland. The main department of described Corporate Investor is located in the Lausanne.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Debiopharm Group, startups are often financed by Gilde Healthcare, Venture Kick, Van Herk Ventures. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Development Corporation, NextStage, Korys. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, PMV Tina Fund, Wellcome Trust.

Besides them, we counted 2 critical employees of this fund in our database.

This Debiopharm Group works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 deals per year. Speaking about the real fund results, this Corporate Investor is 27 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2000. The high activity for fund was in 2012.

Among the most popular portfolio startups of the fund, we may highlight Agendia, Immunexpress, Spinomix. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Switzerland. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are MOOC, Health Care. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Debiopharm Group:
Typical Co-investors
Debiopharm Group is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Debiopharm Group:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Duck Investors -
Excelerate Health Ventures North Carolina, Raleigh, United States
FAM AB Stockholm, Stockholm County, Sweden
Galvanize Colorado, Denver, United States
Halo Business Angel Network County Dublin, Dublin, Ireland
Midwest Growth Partners Iowa, United States, West Des Moines
National Institute of Mental Health Bethesda, Maryland, United States
NPR Holdings -
Race Point Capital Group Massachusetts, United States, Waltham
Taiyo Oil Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

WhiteLab Genomics

Biotechnology
Genetics
$10M12 Sep 2022 Paris, Ile-de-France, France

Novadiscovery

Artificial Intelligence
Biotechnology
CRM
Health Care
Information Technology
Medical
$5M09 Jan 2020 France, Auvergne-Rhône-Alpes

Little Green House

EdTech
Education
10 Nov 2019 Vaud, Switzerland

Coorpacademy

Corporate Training
EdTech
MOOC
$11M26 Oct 2016 Lausanne, Vaud, Switzerland

Immunexpress

Biotechnology
Diagnostic Equipment
Drug Discovery
Genetics
Health Diagnostics
Pharmaceutical
$40M03 Apr 2015 Seattle, Washington, United States

Coorpacademy

Corporate Training
EdTech
MOOC
$3M17 Nov 2014 Lausanne, Vaud, Switzerland

Immunexpress

Biotechnology
Diagnostic Equipment
Drug Discovery
Genetics
Health Diagnostics
Pharmaceutical
$18M05 May 2014 Seattle, Washington, United States

Immunexpress

Biotechnology
Diagnostic Equipment
Drug Discovery
Genetics
Health Diagnostics
Pharmaceutical
$6M05 Mar 2014 Seattle, Washington, United States

BPA Solutions

Software
03 Dec 2013 Vaud, Switzerland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Debiopharm Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: